Effect of GB virus C on response to antiretroviral therapy in HIV-infected Brazilians
Autor(a) principal: | |
---|---|
Data de Publicação: | 2006 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNIFESP |
Texto Completo: | http://repositorio.unifesp.br/handle/11600/28608 http://dx.doi.org/10.1111/j.1468-1293.2005.00339.x |
Resumo: | ObjectivesGB virus C (GBV-C) infection is associated with delayed mortality in HIV-infected people in most, but not all, studies. Previous investigations of the effect of GBV-C viraemia on response to antiretroviral therapy (ART) were inconclusive. To determine the effect of GBV-C on ART, we retrospectively analysed plasma samples taken from patients in a prospective randomized clinical trial of ART in HIV-positive Brazilians.MethodsGBV-C viraemia was characterized by testing stored serum samples from 175 participants by reverse transcriptase-polymerase chain reaction (RT-PCR). Subjects were randomized to receive indinavir (n=59), zidovudine and lamivudine (n=58), or zidovudine, lamivudine and indinavir (n=58). the effect of GBV-C viraemia on the average change in HIV viral load and CD4 count following initiation of therapy was evaluated in a multiple regression analysis.ResultsThe prevalence of GBV-C viraemia was similar to that observed in previous studies (24%). HIV viral load decreased following ART to a significantly greater extent in patients with GBV-C viraemia (by 0.48 log(10) HIV-1 RNA copies/mL, P=0.009, adjusting for age, ART group, and baseline CD4 count). Although there was no significant difference in change in CD4 count between individuals with and without GBV-C viraemia overall, CD4 counts were higher following 48 weeks of therapy in GBV-C viraemic individuals receiving the least potent ART regimen (zidovudine and lamivudine) compared with those without GBV-C infection.ConclusionsGBV-C viraemia is associated with an enhanced reduction of HIV viral load in response to ART. in this study of treatment-naive individuals during 48 weeks of follow up, patients with GBV-C viraemia had reductions in HIV viral load that were approximately 0.5 log copies/mL greater than those found in patients without GBV-C viraemia. This is similar to reductions observed with nucleoside reverse transcriptase inhibitors. |
id |
UFSP_1c68496e9d815ca1dcc9e1385e604b71 |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br:11600/28608 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
Souza, Inara Espinelli Lemes de [UNIFESP]Zhang, W.Diaz, Ricardo Sobhie [UNIFESP]Chaloner, K.Klinzman, D.Stapleton, J. T.Univ IowaIowa City Vet AdmUniversidade Federal de São Paulo (UNIFESP)2016-01-24T12:38:14Z2016-01-24T12:38:14Z2006-01-01Hiv Medicine. Oxford: Blackwell Publishing, v. 7, n. 1, p. 25-31, 2006.1464-2662http://repositorio.unifesp.br/handle/11600/28608http://dx.doi.org/10.1111/j.1468-1293.2005.00339.x10.1111/j.1468-1293.2005.00339.xWOS:000233623500004ObjectivesGB virus C (GBV-C) infection is associated with delayed mortality in HIV-infected people in most, but not all, studies. Previous investigations of the effect of GBV-C viraemia on response to antiretroviral therapy (ART) were inconclusive. To determine the effect of GBV-C on ART, we retrospectively analysed plasma samples taken from patients in a prospective randomized clinical trial of ART in HIV-positive Brazilians.MethodsGBV-C viraemia was characterized by testing stored serum samples from 175 participants by reverse transcriptase-polymerase chain reaction (RT-PCR). Subjects were randomized to receive indinavir (n=59), zidovudine and lamivudine (n=58), or zidovudine, lamivudine and indinavir (n=58). the effect of GBV-C viraemia on the average change in HIV viral load and CD4 count following initiation of therapy was evaluated in a multiple regression analysis.ResultsThe prevalence of GBV-C viraemia was similar to that observed in previous studies (24%). HIV viral load decreased following ART to a significantly greater extent in patients with GBV-C viraemia (by 0.48 log(10) HIV-1 RNA copies/mL, P=0.009, adjusting for age, ART group, and baseline CD4 count). Although there was no significant difference in change in CD4 count between individuals with and without GBV-C viraemia overall, CD4 counts were higher following 48 weeks of therapy in GBV-C viraemic individuals receiving the least potent ART regimen (zidovudine and lamivudine) compared with those without GBV-C infection.ConclusionsGBV-C viraemia is associated with an enhanced reduction of HIV viral load in response to ART. in this study of treatment-naive individuals during 48 weeks of follow up, patients with GBV-C viraemia had reductions in HIV viral load that were approximately 0.5 log copies/mL greater than those found in patients without GBV-C viraemia. This is similar to reductions observed with nucleoside reverse transcriptase inhibitors.Univ Iowa, Dept Internal Med, Roy & Lucille Carver Coll Med, Iowa City, IA 52242 USAIowa City Vet Adm, Med Ctr, Iowa City, IA USAUniversidade Federal de São Paulo, Paulista Sch Med, Div Infect Dis, São Paulo, BrazilUniv Iowa, Coll Publ Hlth, Dept Biostat, Iowa City, IA USAUniversidade Federal de São Paulo, Paulista Sch Med, Div Infect Dis, São Paulo, BrazilWeb of Science25-31engBlackwell PublishingHiv Medicineantiretroviral therapyGB virus type CGBV-Chepatitis GEffect of GB virus C on response to antiretroviral therapy in HIV-infected Braziliansinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP11600/286082022-06-02 09:34:57.599metadata only accessoai:repositorio.unifesp.br:11600/28608Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestopendoar:34652023-05-25T12:16:13.622639Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.en.fl_str_mv |
Effect of GB virus C on response to antiretroviral therapy in HIV-infected Brazilians |
title |
Effect of GB virus C on response to antiretroviral therapy in HIV-infected Brazilians |
spellingShingle |
Effect of GB virus C on response to antiretroviral therapy in HIV-infected Brazilians Souza, Inara Espinelli Lemes de [UNIFESP] antiretroviral therapy GB virus type C GBV-C hepatitis G |
title_short |
Effect of GB virus C on response to antiretroviral therapy in HIV-infected Brazilians |
title_full |
Effect of GB virus C on response to antiretroviral therapy in HIV-infected Brazilians |
title_fullStr |
Effect of GB virus C on response to antiretroviral therapy in HIV-infected Brazilians |
title_full_unstemmed |
Effect of GB virus C on response to antiretroviral therapy in HIV-infected Brazilians |
title_sort |
Effect of GB virus C on response to antiretroviral therapy in HIV-infected Brazilians |
author |
Souza, Inara Espinelli Lemes de [UNIFESP] |
author_facet |
Souza, Inara Espinelli Lemes de [UNIFESP] Zhang, W. Diaz, Ricardo Sobhie [UNIFESP] Chaloner, K. Klinzman, D. Stapleton, J. T. |
author_role |
author |
author2 |
Zhang, W. Diaz, Ricardo Sobhie [UNIFESP] Chaloner, K. Klinzman, D. Stapleton, J. T. |
author2_role |
author author author author author |
dc.contributor.institution.none.fl_str_mv |
Univ Iowa Iowa City Vet Adm Universidade Federal de São Paulo (UNIFESP) |
dc.contributor.author.fl_str_mv |
Souza, Inara Espinelli Lemes de [UNIFESP] Zhang, W. Diaz, Ricardo Sobhie [UNIFESP] Chaloner, K. Klinzman, D. Stapleton, J. T. |
dc.subject.eng.fl_str_mv |
antiretroviral therapy GB virus type C GBV-C hepatitis G |
topic |
antiretroviral therapy GB virus type C GBV-C hepatitis G |
description |
ObjectivesGB virus C (GBV-C) infection is associated with delayed mortality in HIV-infected people in most, but not all, studies. Previous investigations of the effect of GBV-C viraemia on response to antiretroviral therapy (ART) were inconclusive. To determine the effect of GBV-C on ART, we retrospectively analysed plasma samples taken from patients in a prospective randomized clinical trial of ART in HIV-positive Brazilians.MethodsGBV-C viraemia was characterized by testing stored serum samples from 175 participants by reverse transcriptase-polymerase chain reaction (RT-PCR). Subjects were randomized to receive indinavir (n=59), zidovudine and lamivudine (n=58), or zidovudine, lamivudine and indinavir (n=58). the effect of GBV-C viraemia on the average change in HIV viral load and CD4 count following initiation of therapy was evaluated in a multiple regression analysis.ResultsThe prevalence of GBV-C viraemia was similar to that observed in previous studies (24%). HIV viral load decreased following ART to a significantly greater extent in patients with GBV-C viraemia (by 0.48 log(10) HIV-1 RNA copies/mL, P=0.009, adjusting for age, ART group, and baseline CD4 count). Although there was no significant difference in change in CD4 count between individuals with and without GBV-C viraemia overall, CD4 counts were higher following 48 weeks of therapy in GBV-C viraemic individuals receiving the least potent ART regimen (zidovudine and lamivudine) compared with those without GBV-C infection.ConclusionsGBV-C viraemia is associated with an enhanced reduction of HIV viral load in response to ART. in this study of treatment-naive individuals during 48 weeks of follow up, patients with GBV-C viraemia had reductions in HIV viral load that were approximately 0.5 log copies/mL greater than those found in patients without GBV-C viraemia. This is similar to reductions observed with nucleoside reverse transcriptase inhibitors. |
publishDate |
2006 |
dc.date.issued.fl_str_mv |
2006-01-01 |
dc.date.accessioned.fl_str_mv |
2016-01-24T12:38:14Z |
dc.date.available.fl_str_mv |
2016-01-24T12:38:14Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
Hiv Medicine. Oxford: Blackwell Publishing, v. 7, n. 1, p. 25-31, 2006. |
dc.identifier.uri.fl_str_mv |
http://repositorio.unifesp.br/handle/11600/28608 http://dx.doi.org/10.1111/j.1468-1293.2005.00339.x |
dc.identifier.issn.none.fl_str_mv |
1464-2662 |
dc.identifier.doi.none.fl_str_mv |
10.1111/j.1468-1293.2005.00339.x |
dc.identifier.wos.none.fl_str_mv |
WOS:000233623500004 |
identifier_str_mv |
Hiv Medicine. Oxford: Blackwell Publishing, v. 7, n. 1, p. 25-31, 2006. 1464-2662 10.1111/j.1468-1293.2005.00339.x WOS:000233623500004 |
url |
http://repositorio.unifesp.br/handle/11600/28608 http://dx.doi.org/10.1111/j.1468-1293.2005.00339.x |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.none.fl_str_mv |
Hiv Medicine |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
25-31 |
dc.publisher.none.fl_str_mv |
Blackwell Publishing |
publisher.none.fl_str_mv |
Blackwell Publishing |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
|
_version_ |
1783460270154186752 |